30 March 2022 | News
The firm raised almost $60 million (100 million RMB) in the fresh funding
Image credit: shutterstock
China's CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital.
CellOrigin is committed to develop engineered iPSC-derived CAR-macrophage and CAR-NK cell product. Integrating single cell atlas of differentiation, AI and synthetic biology approaches, CellOrigin developed its technology platform to learn from developmental biology in order to optimize more efficient differentiation methods, and to design more effective cell products. Building on its proprietary technology platform of engineering macrophage and DC cells through iPSCs, CellOrigin aims to make engineered clonal iPSC-derived off-the-shelf immune cell products in large scale for cancer immunotherapy applications.
The founding members of the CellOrigin team have rich experiences in cell therapies in academia and industry. The scientific co-founder Dr. Jin Zhang is a principal investigator at Zhejiang University, and was trained at the Boston Children's Hospital/Harvard Medical School before he joined the university in 2017. His team for the first time reported the iPSC-derived CAR-macrophage or CAR-iMac. He is fully committed to enable the next generation of innovative cell products with the continuous input of research on developmental biology and new disruptive technologies.